The Impact of Medicaid Health Homes on Patients With Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02713321|
Recruitment Status : Recruiting
First Posted : March 18, 2016
Last Update Posted : January 14, 2020
|Condition or disease|
|Type 2 Diabetes Mellitus|
|Study Type :||Observational|
|Estimated Enrollment :||13000 participants|
|Official Title:||The Impact of Medicaid Health Homes on Patients With Diabetes|
|Actual Study Start Date :||January 24, 2017|
|Estimated Primary Completion Date :||February 2021|
|Estimated Study Completion Date :||February 2021|
Health Home patients
The cohort is made up of patients with type 2 diabetes, insured by Medicaid, and eligible for participation in a Medicaid Health Home (either due to HIV infection, serious mental illness, substance abuse, or multiple chronic conditions). One group will include patients who participate in the Health Home program.
non-Health Home patients
The second group will include patients who do not participate in the Health Home program, but have type 2 diabetes, are insured by Medicaid, and meet eligibility requirements for the Health Homes.
- Diabetes-related preventable hospitalizations [ Time Frame: up to 5 years ]Incidence of hospitalizations related to diabetes that could have been prevented. Diabetes-related potentially preventable hospitalizations are admissions to a hospital for certain acute illnesses or worsening chronic conditions that might not have required hospitalization had these conditions been managed successfully by primary care providers in outpatient settings.
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02713321
|Contact: Victoria L. Mayer, MD, MS||212 659 firstname.lastname@example.org|
|United States, New York|
|Icahn School of Medicine at Mount Sinai||Recruiting|
|New York, New York, United States, 10029|
|Principal Investigator: Victoria L Mayer, MD, MS|
|Principal Investigator:||Victoria L Mayer, MD, MS||Icahn School of Medicine at Mount Sinai|